NeoPharm Co

NeoPharm Co Equity

The The Equity of NeoPharm Co (092730.KQ) as of Nov 2, 2026 is 195.36 B KRW. In the previous year, The Equity was 176.88 B KRW — a change of 10.44% (higher).

Equity

195.36 BKRW

YoY

10.44%

Last updated:

In 2025, NeoPharm Co's equity was 195.36 B KRW, a 10.44% increase from the 176.88 B KRW equity in the previous year.

The NeoPharm Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
59.29 B KRW
Jan 1, 2019
105.69 B KRW
Jan 1, 2020
117.72 B KRW
Jan 1, 2021
130.30 B KRW
Jan 1, 2022
142.21 B KRW
Jan 1, 2023
160.03 B KRW
Jan 1, 2024
176.88 B KRW
Jan 1, 2025
195.36 B KRW
The NeoPharm Co Equity history
YEAREquityYoY
195.36 BKRW+10.44%
176.88 BKRW+10.54%
160.03 BKRW+12.53%
142.21 BKRW+9.14%
130.30 BKRW+10.69%
117.72 BKRW+11.38%
105.69 BKRW+78.27%
59.29 BKRW+24.60%
47.58 BKRW+23.36%
38.57 BKRW+18.23%
32.62 BKRW+4.74%
31.15 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoPharm Co Stock analysis

What does NeoPharm Co do? NeoPharm Co., Ltd. generates revenue through the development, manufacture, and sale of cosmetics, medical, and health products under its own brand names. The company sells ATOPALM products, which include daily care, intensive care, special care, and baby care items, as well as Derma:B products such as foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, BB creams, sun protectors, white watering serums, and anti-aging eye creams. ZEROID products, featuring creams and lotions for skin barrier recovery and hypoallergenic foaming cleansers for atopic and sensitive skin, also contribute to sales. Additionally, NeoPharm provides original equipment manufacturing (OEM) services for skin drugs, supplying these to other companies. The primary buyers of NeoPharm's products are consumers seeking skincare solutions for daily use, sensitive skin conditions, and medical-grade treatments. ATOPALM targets general skincare and baby care markets, while Derma:B appeals to users looking for comprehensive skincare routines including anti-aging and sun protection. ZEROID focuses on individuals with atopic or sensitive skin requiring gentle, hypoallergenic products. OEM services are purchased by other pharmaceutical companies needing skin drug manufacturing capabilities. NeoPharm's product portfolio is structured around four key brands: ATOPALM, Derma:B, ZEROID, and OEM services. ATOPALM and Derma:B cater to broad consumer segments in the cosmetics and skincare industry, with Derma:B offering a wide range of products for various skin concerns. ZEROID serves a specialized segment for sensitive skin care, and OEM services target business-to-business clients in the pharmaceutical sector. The company's revenue streams are thus diversified across consumer-facing brands and B2B manufacturing contracts. NeoPharm Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing NeoPharm Co's Equity

NeoPharm Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding NeoPharm Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating NeoPharm Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

NeoPharm Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in NeoPharm Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about NeoPharm Co stock

The Equity of NeoPharm Co is 195.36 B KRW in 2025.

The Equity of NeoPharm Co changed from 176.88 B KRW to 195.36 B KRW, representing a 10.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity NeoPharm Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's NeoPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NeoPharm Co

All Key Metrics — NeoPharm Co